Table 2 Physiological results from volume regulated perfusion
From: Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat
DIADOX | DIA5HDDOX | 5HDDOX | DIASAL | 5HDSAL | SALSAL | SALDOX | |
|---|---|---|---|---|---|---|---|
LVDP (mmHg) | 141.5 ± 6.9* | 127.9 ± 4.3 | 108.1 ± 9.3 | 149.5 ± 10.8* | 155.6 ± 13.0* | 162.9 ± 14.7* | 117.1 ± 9.1 |
LVEDP (mmHg) | 9.6 ± 2.5* | 16.0 ± 2.2 | 15.8 ± 2.1 | 10.6 ± 1.8* | 8.2 ± 1.0* | 9.3 ± 1.6* | 18.0 ± 13.2 |
AoP (mmHg) | 103.9 ± 2.2* | 124.2 ± 5.1 | 130.5 ± 7.3 | 82.7 ± 6.0* | 76.0 ± 3.5* | 76.9 ± 3.6* | 133.7 ± 5.0 |
Heart rate (beats per minute) | 300 ± 0 | 300 ± 0 | 300 ± 0 | 300 ± 0 | 300 ± 0 | 300 ± 0 | 300 ± 0 |
dp/dtmax (mmHg/s) | 3697.4 ± 141.0* | 2512.9 ± 302.0 | 2950.7 ± 237.5 | 4583.6 ± 546.9* | 3935.7 ± 213.6* | 3973.6 ± 246.9* | 2777.8 ± 386.9 |
dp/dtmin (mmHg/s) | −2380.6 ± 157.0 | −2176.4 ± 154.8 | −2530.1 ± 251.4 | −2940.8 ± 261.6 | −3041.6 ± 403.1 | 2862.0 ± 295.1 | −2579.8 ± 329.1 |
Coronary flow (ml/min) | 12.5 ± 0 | 12.5 ± 0 | 12.5 ± 0 | 12.5 ± 0 | 12.5 ± 0 | 12.5 ± 0 | 12.5 ± 0 |